Why AbbVie Stock Slumped Today

AbbVie reported robust Q2 results, surpassing analyst expectations with $15.4 billion in revenue (up 7% YoY) and non-GAAP net income of $2.97 per share, largely driven by strong sales of Skyrizi (+62%) and Rinvoq (+42%), offsetting Humira's 58% decline. The company also raised its 2025 adjusted net income guidance. However, the initial market enthusiasm was tempered by news of President Trump's demand that major pharmaceutical companies, including AbbVie, reduce drug prices within 60 days, causing the stock to close lower despite the strong fundamentals.

Analysis

AbbVie demonstrated strong underlying fundamentals in its second-quarter report, exceeding analyst estimates with revenue of $15.4 billion, a 7% year-over-year increase, and non-GAAP EPS of $2.97. The performance was driven by significant growth in its key drugs Skyrizi and Rinvoq, with sales rising 62% and 42% respectively. This robust growth successfully compensated for the anticipated 58% decline in Humira sales following the introduction of biosimilar competition, signaling a successful strategic pivot in its product portfolio. Management underscored its confidence by raising the full-year 2025 adjusted EPS guidance to a range of $11.88 to $12.08. However, this positive operational news was overshadowed by a significant external headwind. A demand from the White House for major pharmaceutical companies, including AbbVie, to reduce prescription drug prices within 60 days introduced substantial regulatory uncertainty. This political pressure effectively neutralized the strong earnings report, causing the stock to relinquish its initial gains and close slightly lower, reflecting a market weighing solid corporate performance against imminent pricing risk.

Key Decisions for Investors

• Investors must weigh the company's strong fundamental performance and upwardly revised guidance against the significant, near-term political risk of mandated drug price reductions.
• The continued sales growth of Skyrizi and Rinvoq is the critical factor for AbbVie's long-term outlook, and their performance should be monitored closely as the primary offset to Humira's decline.
• The 60-day timeline for potential price cuts presents a material risk to future revenue and margins, warranting a cautious stance until there is more clarity on the outcome of the White House's demand.